<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04614311</url>
  </required_header>
  <id_info>
    <org_study_id>171224</org_study_id>
    <nct_id>NCT04614311</nct_id>
  </id_info>
  <brief_title>Strategies Towards Personalised Treatment in Juvenile Idiopathic Arthritis (JIA).</brief_title>
  <acronym>MyJIA</acronym>
  <official_title>Strategies Towards Personalised Treatment in Juvenile Idiopathic Arthritis (JIA): The MyJIA Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oslo University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Research Council of Norway</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Haukeland University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>St. Olavs Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital of North Norway</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Helse Stavanger HF</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Oslo University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Inhibitors of tumour necrosis factor (TNFa) reduce inflammation in patients with juvenile&#xD;
      idiopathic arthritis (JIA), but only 20-40 percent achieve a state of no or very little&#xD;
      disease activity. Tailored glucocorticoid joint injections are widely used (usually in&#xD;
      general anaesthesia), but no controlled studies have addressed the effect of this approach.&#xD;
      In Norway there are unique possibilities for early interventions, rapid escalation of&#xD;
      medication and individualised therapy. The investigators aim to find the optimal ways to&#xD;
      increase disease control and improve quality of life for JIA patients.&#xD;
&#xD;
      The hypothesis is that JIA patients starting TNF-inhibitors with added steroid injection of&#xD;
      inflamed joints, will lead to improved outcomes compared to TNF-inhibitors with no joint&#xD;
      injections, and that therapeutic drug monitoring, modern imaging and biologic and clinical&#xD;
      profiling can be utilised to characterise JIA patients with different anti-TNF responses.&#xD;
&#xD;
      MyJIA is a national investigator initiated 48 weeks RCT of JIA patients starting&#xD;
      TNF-inhibitors; 202 JIA patients will be randomised at baseline to A) concomitant&#xD;
      intra-articular glucocorticoid injections versus B) no injections. Primary endpoint is the&#xD;
      rate of sustained remission from weeks 24 to 36. Possible risk factors for not reaching&#xD;
      remission will be analysed including clinical characteristics, drug antibodies/serum&#xD;
      concentrations, patients' reported health status and preferences, molecular signalling (based&#xD;
      on transcriptional, cellular and genetic risk) and synovitis detected by modern imaging&#xD;
      (ultrasound and whole-body MRI).&#xD;
&#xD;
      Patients will be recruited from all Norwegian health regions through an established&#xD;
      collaboration. Unit of Paediatric Rheumatology, Oslo University Hospital, with an extensive&#xD;
      research track in this field, will be the coordinating centre. Broad research cooperation&#xD;
      across disciplines is established. The trial is highly innovative in evaluating treatment&#xD;
      options and strategies to individualise and optimise the efficacy and safety of JIA&#xD;
      treatment.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 1, 2020</start_date>
  <completion_date type="Anticipated">November 16, 2023</completion_date>
  <primary_completion_date type="Anticipated">August 16, 2023</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Parallel intervention were participants are assigned to either the control group or intervention group.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>The individual who evaluates joints clinically will be blinded to study information.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>The proportion of JIA participants with sustained inactive disease</measure>
    <time_frame>Week 24 to week 36.</time_frame>
    <description>The proportion of participants with sustained, inactive disease from week 24 to week 36.&#xD;
Inactive disease is defined according the 2011 Wallace criteria:&#xD;
No active arthritis†&#xD;
Physician global assessment of disease activity score normal (0)&#xD;
Erythrocyte sedimentation rate (ESR) within normal range&#xD;
Morning stiffness ≤ 15 minutes&#xD;
No active uveitis&#xD;
No fever, rash, serositis, splenomegaly, or generalized lymphadenopathy attributable to JIA&#xD;
In addition, no use of any i.a. or p.o. corticosteroids from week 20 to week 36.&#xD;
†Active arthritis according to the ACR definition:&#xD;
a joint with swelling not due to bony enlargement OR, if no swelling is present&#xD;
limitation of motion accompanied by either pain on motion and/or tenderness.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The proportion of participants with ACR pedi 30% response</measure>
    <time_frame>Baseline to week 6,12 and 24</time_frame>
    <description>American College of Rheumatology (ACR) paediatric 30% response (30% improvement in a minimum of 3 of any 6 variables in the paediatric core set criteria with no more than one of the remaining variables worsening more than 30%).&#xD;
Pediatric core set criteria:&#xD;
Physician's global assessment of disease activity (visual analogue scale (VAS), range 0-100 where 0 represents best possible outcome).&#xD;
Patient's/parent's global assessment of overall well-being (VAS, range from 0-100 where 0 represents best possible outcome)&#xD;
Functional ability (Childhood Health Assessment Questionnaire, CHAQ, lower scores are indicative of better functioning)&#xD;
Number of joints with active arthritis (range 0-71 where 0 represents best possible outcome)&#xD;
Number of joints with limited range of movement (range 0-70 where 0 represents best possible outcome)&#xD;
Erythrocyte sedimentation rate (normalised to a 0-10 scale where 0 represents best possible outcome)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion of participants with ACR pedi 50,70 and 90% response</measure>
    <time_frame>Baseline to week 6, 12 and 24.</time_frame>
    <description>American College of Rheumatology (ACR) paediatric 50, 70 and 90% response (50,70 and 90% improvement in a minimum of 3 of any 6 variables in the pediatric core set (see above) criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Juvenile arthritis disease activity score (JADAS)</measure>
    <time_frame>Baseline to week 6, 12 and 24.</time_frame>
    <description>The JADAS is a composite measure of disease activity with a range from 0 to 101 where 0 represents the best possible outcome and 101 the worst possible outcome.&#xD;
The JADAS is calculated as a sum of scores from:&#xD;
Physician's global assessment of disease activity (visual analogue scale ranging from 0-100 where 0 represents best possible outcome and and 100 the worst possible outcome).&#xD;
Patient's/parent's global assessment of overall well-being (visual analogue scale ranging from 0-100 where 0 represents best possible outcome and and 100 the worst possible outcome)&#xD;
- Erythrocyte sedimentation rate (ESR) (normalized to a 0-10 scale, according to the following formula: (ESR (mm/hour)-20)/10. 0 represents best possible outcome and and 10 the worst possible outcome)&#xD;
Number of joints with active arthritis (range from 0 to 71 where 0 represents best possible outcome and and 71 the worst possible outcome)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to inactive disease</measure>
    <time_frame>Baseline to 48 weeks</time_frame>
    <description>Time (months) until participants reach inactive disease according to the Wallace criteria and JADAS.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants with Minimal Disease Activity</measure>
    <time_frame>Week 26 to 48</time_frame>
    <description>Proportion of Participants with Minimal Disease Activity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in arthritis-related pain severity as measured by pain VAS item</measure>
    <time_frame>48 weeks</time_frame>
    <description>Change from Baseline in Arthritis-Related Pain Severity as Measured by Pain Visual Analog Scale (VAS).&#xD;
The Pain VAS ranges from 0 to 100 where 0 represents no pain and 100 the worst possible level of pain.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">202</enrollment>
  <condition>Juvenile Idiopathic Arthritis</condition>
  <arm_group>
    <arm_group_label>Intervention</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intra-articular corticosteroid injections into active joints</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Comparator</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>No intra-articular injections</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Triamcinolone Hexacetonide 20 MG/ML</intervention_name>
    <description>JIA patients (age 1-18 years) starting TNFi treatment randomised to intervention will receive treatment with intra articular glucocorticoids (triamcinolone hexacetonide) injections in inflamed joints</description>
    <arm_group_label>Intervention</arm_group_label>
    <other_name>Lederspan</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. 1-18 years of age at the time of signing the informed consent.&#xD;
&#xD;
          2. Fulfilment of the International League of Associations for Rheumatology (ILAR)&#xD;
             classification criteria for non-systemic JIA.&#xD;
&#xD;
          3. Clinical indication for starting TNFi treatment according to consensus between at&#xD;
             least two physicians.&#xD;
&#xD;
          4. Naïve to TNFi or prior use of one TNFi (stopped at least 3 months before study&#xD;
             inclusion and no previous TNFi treatment failure).&#xD;
&#xD;
          5. Juvenile Disease Activity Score (JADAS) &gt;1 at baseline and at least one joint with&#xD;
             active arthritis were joint injection is considered.&#xD;
&#xD;
          6. Willing to give written consent (participant ≥ 16, guardians if &lt; 16 years of age,&#xD;
             both participants and guardians if 16-18) and comply with the requirements of the&#xD;
             study protocol.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Medical Conditions&#xD;
&#xD;
          1. Major comorbidity including uncontrolled infectious, neurological or mental disease,&#xD;
             malignant disease, severe heart failure, severe renal failure, active ulcus&#xD;
             ventriculi, and uncontrolled diabetes mellitus.&#xD;
&#xD;
             Prior/Concomitant Therapy&#xD;
&#xD;
          2. Used two or more TNFi.&#xD;
&#xD;
          3. Corticosteroid use (including i.a. injection) less than 4 weeks prior to&#xD;
             randomisation.&#xD;
&#xD;
             Other Exclusions&#xD;
&#xD;
          4. Known hypersensitivity to Triamcinolone hexacetonide (Lederspan) or any of the&#xD;
             excipients (sorbitol, polysorbate or benzyl alcohol).&#xD;
&#xD;
          5. Concomitant therapy with CYP3A-inhibitors or digitalis glycosides.&#xD;
&#xD;
          6. Known inherited fructose intolerance&#xD;
&#xD;
          7. Presence of hepatitis B surface antigen (HBsAg) at screening.&#xD;
&#xD;
          8. Positive hepatitis C antibody test result at screening or within 12 months prior to&#xD;
             starting study treatment.&#xD;
&#xD;
          9. Evidence of active or latent tuberculosis (TB) as documented by medical history and&#xD;
             examination, chest X-rays (front), and TB testing. The choice of TB tests will be made&#xD;
             by the investigator according to local licensing and standard of care.&#xD;
&#xD;
         10. Having received live vaccines less than two weeks prior to randomisation.&#xD;
&#xD;
         11. Drug / alcohol abuse which hampers adherence to the study protocol.&#xD;
&#xD;
         12. Language barriers that hampers adherence to the study protocol.&#xD;
&#xD;
         13. Pregnancy or breast-feeding.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pernille H Bøyesen, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oslo University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Anna-Birgitte Aga, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oslo University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Berit Flatø, Prof</last_name>
    <role>Study Director</role>
    <affiliation>Oslo University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Berit Flatø, Prof</last_name>
    <phone>004723070000</phone>
    <email>berit.flato@medisin.uio.no</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Pernille Bøyesen, MD PhD</last_name>
    <phone>004795780514</phone>
    <email>pernilleboyesen@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>St Olavs Hospital</name>
      <address>
        <city>Trondheim</city>
        <state>Trønderlag</state>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marite Rygg, Prof</last_name>
      <phone>004772 57 30 00</phone>
      <email>marite.rygg@ntnu.no</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Haukeland University Hospital</name>
      <address>
        <city>Bergen</city>
        <zip>5021</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karin B Tylleskär, MD</last_name>
      <phone>00 47 55 97 50 00</phone>
      <email>karin.tylleskar@helse-bergen.no</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oslo University Hospital</name>
      <address>
        <city>Oslo</city>
        <zip>0424</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pernille Bøyesen, MD PhD</last_name>
      <phone>004791502770</phone>
      <email>pernilleboyesen@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Anna_Birgitte Aga, MD PhD</last_name>
      <phone>004791502770</phone>
      <email>anna.birgitte.aga@gmail.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Stavanger University Hospital</name>
      <address>
        <city>Stavanger</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bjørn Barstad, MD PhD</last_name>
      <phone>+4751518000</phone>
      <email>bjorn.barstad@sus.no</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital of North Norway</name>
      <address>
        <city>Tromsø</city>
        <zip>9019</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ellen B Nordal, Ass Prof</last_name>
      <phone>00 47 776 26000</phone>
      <email>Ellen.Berit.Nordal@unn.no</email>
    </contact>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>October 28, 2020</study_first_submitted>
  <study_first_submitted_qc>October 28, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 3, 2020</study_first_posted>
  <last_update_submitted>April 30, 2021</last_update_submitted>
  <last_update_submitted_qc>April 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Oslo University Hospital</investigator_affiliation>
    <investigator_full_name>Berit Flatø</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Juvenile</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Triamcinolone</mesh_term>
    <mesh_term>Triamcinolone Acetonide</mesh_term>
    <mesh_term>Triamcinolone hexacetonide</mesh_term>
    <mesh_term>Triamcinolone diacetate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

